Added to YB: 2024-10-29
Pitch date: 2024-10-26
LONN.SW [bullish]
Lonza Group AG
-5.82%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
Market Cap
CHF 41.0B
Pitch Price
CHF 555.51
Price Target
N/A
Dividend
0.69%
EV/EBITDA
24.38
P/E
65.09
EV/Sales
6.78
Sector
Life Sciences Tools and Services
Category
growth
10 Companies for the next 10 years - Lonza Group AG
LONN.SW: Leading drug manufacturer, strong in biologics CDMO (45% sales), small molecules (15%), capsules (25%). High-single-digit industry growth expected. Take-or-pay contracts ensure visibility. Biotech slowdown impacting margins, but easing expected. Risks: pricing, regulation, competition. Growth driven by biologics investments, Roche assets, US reshoring.
Read full article (1 min)